Cargando…

Two Cases of ALK-Altered Cancers of Unknown Primary Diagnosed by Immunohistochemistry

Cancer of unknown primary (CUP) accounts for 5% of all malignancies. Patients with CUP may live averagely for 8 months after diagnosis, and thus, rapid and reasonable diagnosis is necessary. Among patients with CUP, anaplastic lymphoma kinase (ALK)-overexpressing CUPs, whose primary sites were confi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Yoriko, Shimazu, Kazuhiro, Fukuda, Koji, Yoshida, Taichi, Taguchi, Daiki, Shinozaki, Hanae, Nanjyo, Hiroshi, Shibata, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832189/ https://www.ncbi.nlm.nih.gov/pubmed/35221965 http://dx.doi.org/10.1159/000521157

Ejemplares similares

Pulmonary Artery Intimal Sarcoma in a Patient with Lynch Syndrome: Response to an Immune Checkpoint Inhibitor
por: Mounai, Yue, et al.
Publicado: (2023)

Clinical Course of a Rare Epstein-Barr Virus-Associated Smooth Muscle Tumor and Its Genomic Analysis
por: Miyahara, Jun, et al.
Publicado: (2023)

Curcumin analog, GO‐Y078, overcomes resistance to tumor angiogenesis inhibitors
por: Shimazu, Kazuhiro, et al.
Publicado: (2018)

Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture
por: Yoshida, Taichi, et al.
Publicado: (2021)

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
por: Hashimoto, Hiroshi, et al.
Publicado: (2022)

Malakoplakia with aberrant ALK expression by immunohistochemistry: a case report
por: Zhang, Xiao-Ying, et al.
Publicado: (2023)

ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients
por: Uruga, Hironori, et al.
Publicado: (2018)

Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site
por: Selves, Janick, et al.
Publicado: (2018)

Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement
por: Shan, Ling, et al.
Publicado: (2014)

Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry
por: Wang, Jiandong, et al.
Publicado: (2014)

Helicobacter pylori Reinfection Diagnosed by Endoscopic and Histologic Recurrence in a Patient with Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
por: Sugiyama, Toshiro, et al.
Publicado: (2023)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Lack of expression of ALK and CD30 in breast carcinoma by immunohistochemistry irrespective of tumor characteristics
por: Nassif, Samer, et al.
Publicado: (2019)

Immunohistochemistry for (Pro)renin Receptor in Humans
por: Morimoto, Satoshi, et al.
Publicado: (2021)

Soft Tissue Tumor Without Neurofibromatosis Type 1 With Histopathological Suspicion of Atypical Neurofibromatous Neoplasm of Uncertain Biological Potential (ANNUBP)
por: Tsuchie, Hiroyuki, et al.
Publicado: (2023)

Successful Alectinib Treatment for Carcinoma of Unknown Primary with EML4-ALK Fusion Gene: A Case Report
por: Sugiyama, Keiji, et al.
Publicado: (2021)

Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced ALK-Positive NSCLC
por: Noé, Johannes, et al.
Publicado: (2022)

Targeting anaplastic lymphoma kinase (ALK) gene alterations in neuroblastoma by using alkylating pyrrole-imidazole polyamides
por: Ota, Yoko, et al.
Publicado: (2021)

Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening
por: Lee, Jeeyun, et al.
Publicado: (2015)

Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)
por: Takeuchi, K., et al.
Publicado: (2016)

Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry
por: Sandeck, Helmut P, et al.
Publicado: (2010)

Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients
por: Martinez, Pablo, et al.
Publicado: (2013)

Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is Required
por: Pickett, Justine L., et al.
Publicado: (2017)

Successful Preservation of the Bladder in a Case of Inflammatory Myofibroblastic Tumor with the Diagnostic Efficacy of ALK/p80 Immunohistochemistry and FISH Analysis: Case Report and Review of the Literature
por: Kato, Manabu, et al.
Publicado: (2017)

Usefulness of BATF3 Immunohistochemistry in Diagnosing Classical Hodgkin Lymphoma
por: Benckendorff, Julian, et al.
Publicado: (2021)

Progressive renal insufficiency related to ALK inhibitor, alectinib
por: Nagai, Kojiro, et al.
Publicado: (2018)

Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer
por: Hout, David R., et al.
Publicado: (2017)

Thoracic extradural malignant melanoma with unknown primary
por: Takagi, Yasutaka, et al.
Publicado: (2020)

Langerhans cell histiocytosis of the sternum
por: Tsuchie, Hiroyuki, et al.
Publicado: (2009)

Occult Breast Cancer Presenting as Metastatic Adenocarcinoma of Unknown Primary: Clinical Presentation, Immunohistochemistry, and Molecular Analysis
por: Wang, Jue, et al.
Publicado: (2012)

Mismatch Repair Protein Expression in Endometrial Cancer: Assessing Concordance and Unveiling Pitfalls in Two Different Immunohistochemistry Assays
por: Yoshida, Hiroshi, et al.
Publicado: (2023)

Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing
por: Jurmeister, Philipp, et al.
Publicado: (2021)

Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer
por: Ando, Koji, et al.
Publicado: (2015)

Adverse renal effects of anaplastic lymphoma kinase inhibitors and the response to alectinib of an ALK+ lung cancer patient with renal dysfunction
por: Shimada, Midori, et al.
Publicado: (2017)

Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative
por: Ma, Di, et al.
Publicado: (2016)

Histopathology and immunohistochemistry of choroidal melanocytoma demonstrated by local resection: A case report
por: Goto, Hiroshi, et al.
Publicado: (2021)

Xp11.2 Translocation Renal Cell Carcinoma Diagnosed by Immunohistochemistry and Cytogenetics
por: Dey, Biswajit, et al.
Publicado: (2016)

Role of immunohistochemistry in diagnosing round-cell tumours affecting the oral and maxillofacial regions
por: Kaur, Harpreet, et al.
Publicado: (2023)

Immunohistochemistry
por: HAWES, DEBRA, et al.
Publicado: (2009)

Short progression‐free survival of ALK inhibitors sensitive to secondary mutations in ALK‐positive NSCLC patients
por: Haratake, Naoki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6p4ev0n15es7rprs0njc6ac85d